Ads
related to: actemra patient information pdf free
Search results
Results From The WOW.Com Content Network
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
FDA Approves ACTEMRA ® for Children Living with a Rare Form of Arthritis Medicine Offers a New Option for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (PJIA) SOUTH SAN FRANCISCO ...
Although the use of the term DMARDs was first propagated in rheumatoid arthritis (hence their name), the term has come to pertain to many other diseases, such as Crohn's disease, lupus erythematosus, Sjögren syndrome, immune thrombocytopenic purpura, myasthenia gravis, sarcoidosis, and various others. [citation needed]
2010: Actemra (tocilizumab): The first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody approved to treat rheumatoid arthritis. 2011: Zelboraf (vemurafenib): For the treatment of metastatic melanoma caused by BRAF mutation. 2012: Erivedge (vismodegib): Treatment for advanced basal-cell carcinoma (BCC).
FDA Approves Expanded Indication for ACTEMRA ® in Rheumatoid Arthritis SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY ...
Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab.